company background image
FBIO logo

Fortress Biotech NasdaqCM:FBIO Stock Report

Last Price

US$1.73

Market Cap

US$32.7m

7D

-8.0%

1Y

-82.9%

Updated

21 Feb, 2024

Data

Company Financials +

Fortress Biotech, Inc.

NasdaqCM:FBIO Stock Report

Market Cap: US$32.7m

FBIO Stock Overview

Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products.

FBIO fundamental analysis
Snowflake Score
Valuation4/6
Future Growth5/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Fortress Biotech, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Fortress Biotech
Historical stock prices
Current Share PriceUS$1.73
52 Week HighUS$13.50
52 Week LowUS$1.24
Beta1.51
1 Month Change-13.07%
3 Month Change-21.36%
1 Year Change-82.86%
3 Year Change-97.02%
5 Year Change-94.64%
Change since IPO-98.95%

Recent News & Updates

There's No Escaping Fortress Biotech, Inc.'s (NASDAQ:FBIO) Muted Revenues Despite A 99% Share Price Rise

Dec 29
There's No Escaping Fortress Biotech, Inc.'s (NASDAQ:FBIO) Muted Revenues Despite A 99% Share Price Rise

Recent updates

There's No Escaping Fortress Biotech, Inc.'s (NASDAQ:FBIO) Muted Revenues Despite A 99% Share Price Rise

Dec 29
There's No Escaping Fortress Biotech, Inc.'s (NASDAQ:FBIO) Muted Revenues Despite A 99% Share Price Rise

There Is A Reason Fortress Biotech, Inc.'s (NASDAQ:FBIO) Price Is Undemanding

Aug 18
There Is A Reason Fortress Biotech, Inc.'s (NASDAQ:FBIO) Price Is Undemanding

Fortress to get NIH funding for trial of Triplex vaccine to prevent CMV in liver transplant patients

Aug 11

David Jin is the new finance chief of Fortress Biotech

Jul 22

Is Fortress Biotech (NASDAQ:FBIO) Using Debt Sensibly?

Jan 11
Is Fortress Biotech (NASDAQ:FBIO) Using Debt Sensibly?

Fortress Biotech (NASDAQ:FBIO) Has Debt But No Earnings; Should You Worry?

Sep 28
Fortress Biotech (NASDAQ:FBIO) Has Debt But No Earnings; Should You Worry?

Does Fortress Biotech (NASDAQ:FBIO) Have A Healthy Balance Sheet?

Jun 04
Does Fortress Biotech (NASDAQ:FBIO) Have A Healthy Balance Sheet?

Is Fortress Biotech (NASDAQ:FBIO) Using Too Much Debt?

Mar 04
Is Fortress Biotech (NASDAQ:FBIO) Using Too Much Debt?

When Will Fortress Biotech, Inc. (NASDAQ:FBIO) Turn A Profit?

Feb 06
When Will Fortress Biotech, Inc. (NASDAQ:FBIO) Turn A Profit?

Read This Before Buying Fortress Biotech, Inc. (NASDAQ:FBIO) Shares

Jan 11
Read This Before Buying Fortress Biotech, Inc. (NASDAQ:FBIO) Shares

Fortress Biotech founded Cyprium's CUTX-101 nabs accelerated review for copper metabolism disorder

Dec 15

Is Fortress Biotech, Inc. (NASDAQ:FBIO) Popular Amongst Insiders?

Dec 15
Is Fortress Biotech, Inc. (NASDAQ:FBIO) Popular Amongst Insiders?

Health Check: How Prudently Does Fortress Biotech (NASDAQ:FBIO) Use Debt?

Nov 19
Health Check: How Prudently Does Fortress Biotech (NASDAQ:FBIO) Use Debt?

Fortress Biotech EPS misses by $0.02, misses on revenue

Nov 09

Shareholder Returns

FBIOUS BiotechsUS Market
7D-8.0%0.6%-0.5%
1Y-82.9%5.8%22.3%

Return vs Industry: FBIO underperformed the US Biotechs industry which returned 5.8% over the past year.

Return vs Market: FBIO underperformed the US Market which returned 22.3% over the past year.

Price Volatility

Is FBIO's price volatile compared to industry and market?
FBIO volatility
FBIO Average Weekly Movement17.1%
Biotechs Industry Average Movement11.5%
Market Average Movement6.0%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.1%

Stable Share Price: FBIO's share price has been volatile over the past 3 months.

Volatility Over Time: FBIO's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2006187Lindsay Rosenwaldhttps://www.fortressbiotech.com

Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino an oral minocycline drug for the treatment of moderate to severe acne; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Exelderm cream for antifungal intended for topical use; Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Amzeeq; Zilxi; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children.

Fortress Biotech, Inc. Fundamentals Summary

How do Fortress Biotech's earnings and revenue compare to its market cap?
FBIO fundamental statistics
Market capUS$32.71m
Earnings (TTM)-US$78.31m
Revenue (TTM)US$61.97m

0.5x

P/S Ratio

-0.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
FBIO income statement (TTM)
RevenueUS$61.97m
Cost of RevenueUS$155.48m
Gross Profit-US$93.51m
Other Expenses-US$15.20m
Earnings-US$78.31m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-4.26
Gross Margin-150.89%
Net Profit Margin-126.36%
Debt/Equity Ratio-397.1%

How did FBIO perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.